Orthopediatrics Corp. · NASDAQ:KIDS
Orthopediatrics — Investor Presentation (August 2026)
33 slides from Orthopediatrics's investor presentation, Aug 4, 2026
Slide 1: 2026 Investor Presentation
2026 Investor Presentation www.OrthoPediatrics.com
Slide 2: Forward-Looking Statements
22 0 2 6 / / Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business,
Slide 3: Pediatric patients treated since inception
32 0 2 6 / / pediatric patients treated since inception + 1,382,000 OrthoPediatrics was founded on the cause of impacting the lives of children with orthopedic conditions 1
Slide 4: Historical Challenges of Pediatric Orthopedics
01 Children’s unique clinical conditions Existing solutions are re-purposed from adult implants Limited development of new technologies No specialized sales force in Pediatric Orthopedics Limited industry support of clinical education 02 03 04 05 42 0 2 6 / / Historical Challenges of Pediatric Ortho
Slide 5: OrthoPediatrics Solution
52 0 2 6 / / OrthoPediatrics Solution 01 02 03 04 05 Product development focused exclusively on pediatric patients Broadest pediatric specific portfolio in the industry Delivering first in market novel surgical solutions Only global commercial channel to market Leading provider of surgeon clinical e
Slide 6: Only Focused Pediatric Orthopedic Company
62 0 2 6 / / Only Focused Pediatric Orthopedic Company Consistent YoY Growth Since Inception 1 Excluding COVID-impacted 2020 +90 unique pediatric systems Consistent cadence of innovative product launches Expanding suite of enabling technologies Internal R&D, acquisitions, and partnerships Only globa
Slide 7: Total Global Addressable Market – $6.2B
72 0 2 6 / / Total Global Addressable Market – $6.2B Competitive Dynamics $610M Trauma & Deformity Correction Implants $340M Scoliosis Fusion Impants $80M Scoliosis Non- Fusion Implants $60 EOS Implants $775M Specialty Bracing $250M Sports Medicine Implants $165M Growing Implants $500 Enabling Techn
Slide 8: Strategic Pillars
82 0 2 6 / / Strategic Pillars 02 Provide a broad product portfolio uniquely designed to treat children, surround pediatric orthopedic surgeons covering their needs 04 Expand addressable market through aggressive investment in R&D and select M&A opportunities 05 Train next generation of pediatric or
Slide 9: Focus on High-Volume Children's Hospitals
92 0 2 6 / / Comments ~1,520 Fellowship Trained Pediatric Surgeons Majority of Pediatric Centers are Teaching Hospitals Centers Treat Most Complex Pediatric Conditions ~80% of Pediatric Surgeons time is Non-Surgical 01 02 03 01 Focus on High-Vol Children’s Hospitals Current US Target Market – $1.6B
Slide 10: Years of Foundation Building
102 0 2 6 / / 20 Years of Foundation Building Cannulated Screws 2008 PediNail System 2012 RESPONSE Scoliosis 2016 Orthex® External Fixation 2020 MD Orthopedics® Bracing 2025 LAUNCHLAUNCH LAUNCH ACQUIRE Hip Systems LAUNCH ACQUIRE 90+ Systems Broadest Portfolio across: Trauma & Def Scoliosis Sports Me
Slide 11: Provide a Broad Product Portfolio
112 0 2 6 / / 02 Provide a Broad Product Portfolio Strong Foundation of Implants
Slide 12: Strong Innovation & R&D
122 0 2 6 / / Strong Innovation & R&D 02 Provide a Broad Product Portfolio Multi-year super cycle • Entered a multi-year product super cycle, with multiple launches expected over several years Building Platforms • Focus on platform & product family development rather than isolated products Surgeon-l
Slide 13: Innovation RoadMap
132 0 2 6 / / Innovation RoadMap02 Provide Broad Product Portfolio Playbook Surgical Response Rib & Pelvic PNP | Tibia Limited Iota Motion DF2® 3P Hip PlatformGIRO VERTEGLIDE Traxio Halo Gravity Entering a “Super-Cycle” of Differentiated Product Launches LimitedLimitedLaunchedLaunchedLaunched
Slide 14: Innovation RoadMap: Super-Cycle of Product Launches
142 0 2 6 / / Innovation RoadMap02 Provide Broad Product Portfolio Entering a “Super-Cycle” of Differentiated Product Launches PNP | Retro 3P Small | Mini Predictive Planning eLLi Tractor Fix VerAxis Scoliosis PNP | SD Pin to Bar Ex- Fix 3P | Knee Q3 2026 Q4 2026 Q1 2027 Q2 2027 Q3 2027 Q4 2027
Slide 15: Accelerating Sales Growth Post-IPO
152 0 2 6 / / Accelerating Sales Growth Post-IPO Through Strategic Investment and Innovation $37.3 $45.6 $57.6 $72.6 $71.1 $98.0 $122.3 $148.7 $204.7 $236.3 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Total Revenue ($M) CAGR20252016 11%23290U.S. Independent Sales Consultants 10%$17$7MInstrumen
Slide 16: Increasing ROI on Sets Deployed
162 0 2 6 / / Increasing ROI 12 18 18 14 20 22 21 17 10 0% 5% 10% 15% 20% 25% 30% $0 $50 $100 $150 $200 $250 $300 2018 2019 2020 2021 2022 2023 2024 2025 2026 Set Deployment Efficiencies Reducing set deployments as a percentage of revenue while continuing to take share Revenue (Left) Set Deployment
Slide 17: Strategic Acquisitions & Partnerships
172 0 2 6 / / Strategic Acquisitions & Partnerships 202020192017 2022 04 Expand Market with M&A 2021 2023 2024 2026 Partnership Acquisition
Slide 18: OPSB Key Growth-Strategic Objectives
182 0 2 6 / / OPSB Key Growth-Strategic Objectives Aggressive market-based clinic expansion strategy Accelerate R&D with increasing number of YoY launches Scale OPSB selling channel and sales force – grow with current portfolio of products Launch 4 products in 2024 and 5 in 2025 18 new markets by 20
Slide 19: OPSB Market Expansion
192 0 2 6 / / OPSB Market Expansion Pace of Market Expansion +4 markets in 2025 +6 markets in 2026 +8 markets in 2027 OPSB clinics expected to be in 27 territories in 2027 out of 80 target territories
Slide 20: OPSB ROI and Timing for Clinic Expansion
202 0 2 6 / / OPSB ROI and Timing for Clinic Expansion 1-4 Clinics per market expected Acqui-HireGreenfield $500K-$1M$200k-$500kInitial Investment Positive EBITDA by end of first full year Positive EBITDA by end of first full yearEBITDA Goal Within first yearAfter first full yearFCF Goal Break even
Slide 21: OPSB Opportunity – $2.2B
212 0 2 6 / / Motion Assist Devices Fracture Fixation Devices Specialty Casting Spine Halo Traction, Other Specialty Solutions 300 U.S. Pediatric Centers U.S. Potential Target Market 1 — $1.0B OPSB Opportunity – $2.2B 2 0 2 5 / / 1 Management’s Estimate as of January 2026 Levity Device for Gait Assi
Slide 22: Physician Education and Awareness
222 0 2 6 / / Physician Education and Awareness OP Hands-on sales training and support • Annually invests 3% of sales on clinical education • Conducts >700 product/training sessions per year Continuous education • Major Sponsor of the prominent pediatric orthopedic societies Market development • Fos
Slide 23: Pediatric Systems Revenue by Product Family
232 0 2 6 / / Trauma & Deformity +19% CAGR 14 68 2016 2025 $26.8 $166.3 2016 2025 Pediatric Systems Revenue +22% CAGR Scoliosis >4X Growth 3 17 2016 2025 $9.3 $66.0 2016 2025 Pediatric Systems Revenue >6X Growth 2025 Revenue by Product Family Trauma & Deformity Scoliosis Sports Medicine70% of Revenu
Slide 24: Strong History of Y/Y Growth
242 0 2 6 / / $0.6 $3.0 $7.1 $10.2 $16.1 $19.6 $23.7 $31.0 $37.3 $45.6 $57.6 $72.6 $71.1 $98.0 $122.3 $148.7 $204.7 $236.3 $267.0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Strong History of Y/Y Growth ($M) 400% 137% 44% 58% 22% 21% 31% 20% 22% 26%
Slide 25: Seasonality Drives Stronger Performance in Summer Months and Holidays
252 0 2 6 / / Seasonality Drives Stronger Performance in Summer Months and Holiday Periods 22% 27% 26% 25% 19% 27% 29% 25% 21% 27% 27% 25% 22% 26% 27% 26% 22% 26% 26% 26% 22% 26% 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q Re ve nu e as % o f T ot al Y ea r 2021 2022 2023 Reven
Slide 26: Income Statement Summary
262 0 2 6 / / FY2025FY2024FY2023 $236.3$204.7$148.7Revenue 15%38%22%Growth % $172.7$148.6$111.3Gross profit 73%73%75%Margin % $211.9$183.6$138.0Operating expenses ($39.2)($35.0)($26.8)Operating loss ($39.6)($37.8)($21.0)Net (loss) income ($1.69)($1.64)($0.92)EPS diluted Income Statement Summary ($ i
Slide 27: Adjusted EBITDA Reconciliation
272 0 2 6 / / Adjusted EBITDA Reconciliation Three Months Ended June 30, 20262025 ($7.2)($7.1)Net loss 2.51.1Interest expense, net 0.3(4.7)Other expense (income), net 0.3-Income tax charge 5.75.1Depreciation and amortization 4.25.3Stock-based compensation -3.0Restructuring charges 0.20.6Tariffs 0.80
Slide 28: Adjusted EPS Reconciliation
282 0 2 6 / / Adjusted EPS Reconciliation Three Months Ended June 30, 20262025 ($0.30)($0.30)Loss per share, diluted (GAAP) 0.010.03Tariffs -0.13Restructuring charges 0.030.02Acquisition related costs -0.01Minimum purchase commitment cost ($0.26)($0.11)Adjusted loss per share, diluted (non-GAAP)
Slide 29: Free Cash Flow
292 0 2 6 / / Free Cash Flow ($M) $9 $15 $(21) $(17) $(30) $(13) ($50) ($40) ($30) ($20) ($10) $0 $10 $20 $30 2024 2025 Cash Used For Working Capital Sets Deployed Adj. EBITDA ($42) ($15) $4 $7 $(5) $(3) $(13) $(7) ($30) ($25) ($20) ($15) ($10) ($5) $0 $5 $10 $15 2Q25 2Q26 Cash Used For Working Capi
Slide 30: Balance Sheet
302 0 2 6 / / Balance Sheet Assets $47.9Cash, cash equivalents & short-term investments 61.0Accounts receivable 137.6Inventory (net) 6.1Other current assets 252.5Total Current Assets 48.6PP&E (net) 210.3Intangibles and goodwill $511.4Total Assets Liabilities $22.2Accounts payable 99.6Debt 41.8Accrue
Slide 31: 2026 Guidance
312 0 2 6 / / 2026 Guidance FY2026 $265.0 to $269.0Revenue ~$25.0Adjusted EBITDA BreakevenFree Cash Flow FY2026 12% to 14%2026 Total Revenue Growth % ~$10.0Set Deployment Assumptions Full Year 2026 Guidance ($ in Millions)
Slide 32: Investment Summary
322 0 2 6 / / Investment Summary Only diversified company focused exclusively on pediatric orthopedics Large, underpenetrated market opportunity in pediatrics Highly concentrated customer base with targeted commercial strategy Broad product portfolio with innovative solutions Only provider committed
Slide 33: 2850 Frontier Drive Warsaw, IN 465852 ph: 574.268.6379 or 877.268.6339 fax: 574.268.6302 www.OrthoPediatrics.com2
2850 Frontier Drive Warsaw, IN 465852 ph: 574.268.6379 or 877.268.6339 fax: 574.268.6302 www.OrthoPediatrics.com2 0 2 6 / /
OrthoPediatrics — Investor Presentation (August 2026) on 6ix